Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-PIPAC Trial
2024-518938-81-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic cancer (PC), sponsored by Policlinico Gemelli. Primary endpoint: Disease Control Rate (DCR). Planned start Dec 2024; status: authorised.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2024-518938-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518938-81-00.